EIKN (NASDAQ:EIKN) Posts Quarterly Earnings Results, Misses Estimates By $0.99 EPS

EIKN (NASDAQ:EIKN) posted its earnings results on Monday. The company reported ($2.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.47) by ($0.99), FiscalAI reports.

EIKN Trading Up 4.8%

EIKN stock traded up $0.55 on Wednesday, hitting $12.08. 155,237 shares of the stock traded hands, compared to its average volume of 357,494. The firm has a fifty day moving average of $11.08. EIKN has a 1 year low of $7.90 and a 1 year high of $17.40.

Analyst Ratings Changes

A number of research analysts have issued reports on EIKN shares. Wedbush reduced their price objective on shares of EIKN from $7.00 to $5.00 and set an “underperform” rating on the stock in a research report on Tuesday. Morgan Stanley assumed coverage on shares of EIKN in a research report on Monday, March 2nd. They issued an “overweight” rating and a $32.00 target price for the company. Zacks Research raised shares of EIKN to a “hold” rating in a research note on Friday, February 27th. Mizuho assumed coverage on shares of EIKN in a research report on Monday, March 2nd. They set an “outperform” rating and a $26.00 price target on the stock. Finally, Bank of America started coverage on shares of EIKN in a research note on Monday, March 2nd. They issued a “buy” rating and a $34.00 price target for the company. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, EIKN has a consensus rating of “Moderate Buy” and a consensus target price of $25.20.

About EIKN

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.